You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.
A genome-wide association study focused on hundreds of immune cell features identified genetic risk variants involved in several autoimmune conditions.
An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.
Sequencing and other analyses helped uncover a JAK1 variant within a patient with an unknown autoimmune disorder disease and find a treatment approach.
With genome sequences for nearly 900 individuals with primary immunodeficiency, researchers identified candidate genes and common variant contributors.
Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.
A large genome-wide association study that included more than 400,000 UK Biobank participants led to 69 new or known loci associated with 25-hydroxyvitamin D levels.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
Investigators analyzed the expression of protein-coding genes in 18 blood immune cell populations, comparing the expression profiles with those in other cell and tissue types.
During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.